Research and Development Department, Laboratorios LETI, S.L., Calle del Sol No. 5, Tres Cantos, Madrid, Spain.
Int Arch Allergy Immunol. 2010;153(1):61-9. doi: 10.1159/000301580. Epub 2010 Mar 31.
Polymerised allergenic extracts (allergoids) are commonly used in allergen immunotherapy. Clinical efficacy and safety of these extracts have been demonstrated. Recently, allergen sequences have been identified by mass spectrometry in depigmented and polymerised (Dpg-Pol) extracts. The objectives of this study were to investigate the presence of allergens in Dpg-Pol extracts of house dust mite and to analyze the immunological changes induced by these extracts in asthmatic patients enrolled in a double-blind, placebo-controlled study.
Dpg-Pol extracts were manufactured and vaccines with a composition of 50% Dermatophagoides pteronyssinus and 50% D. farinae (100 HEPL/ml) were prepared. Allergen composition was analyzed by mass spectrometry. Patients with asthma and rhinoconjunctivitis were treated in a 1-year, double-blind, placebo-controlled, parallel-group study with 6 up-dosing and monthly maintenance injections. Specific IgE and IgG4 titres to D. pteronyssinus, Der p 1 and Der p 2 were measured in patients' sera using the CAP system and direct ELISA experiments.
Sequences from the major allergens Der p 1 and Der p 2 and from other allergens were identified in native and Dpg-Pol extracts. There was a statistically significant increase in specific IgG4, a decrease in the ratio of IgE/IgG4 to D. pteronyssinus and a significant increase in specific IgG4 to Der p 1 and Der p 2 in the patients allotted to active treatment.
The detection of allergen sequences suggests preservation of major and minor allergens in Dpg-Pol allergoids from house dust mites. Efficacy in asthma treatment and the increase in specific IgG4 seem to be associated with the presence of major allergens in Dpg-Pol allergen extracts.
聚合过敏原提取物(过敏原)常用于过敏原免疫治疗。这些提取物的临床疗效和安全性已得到证实。最近,通过质谱法在脱色和聚合(Dpg-Pol)提取物中鉴定出过敏原序列。本研究的目的是研究屋尘螨 Dpg-Pol 提取物中过敏原的存在,并分析这些提取物在接受双盲、安慰剂对照研究的哮喘患者中引起的免疫学变化。
制造 Dpg-Pol 提取物,并制备含有 50%粉尘螨和 50%屋尘螨(100 HEPL/ml)的疫苗。通过质谱法分析过敏原组成。患有哮喘和鼻结膜炎的患者在为期 1 年的双盲、安慰剂对照、平行组研究中接受治疗,共进行 6 次加量和每月维持注射。使用 CAP 系统和直接 ELISA 实验测量患者血清中对粉尘螨、Der p 1 和 Der p 2 的特异性 IgE 和 IgG4 滴度。
在天然和 Dpg-Pol 提取物中鉴定出主要过敏原 Der p 1 和 Der p 2 以及其他过敏原的序列。在分配到活性治疗的患者中,特异性 IgG4 显著增加,对粉尘螨的 IgE/IgG4 比值降低,对 Der p 1 和 Der p 2 的特异性 IgG4 显著增加。
过敏原序列的检测表明屋尘螨 Dpg-Pol 过敏原中主要和次要过敏原得到保留。在哮喘治疗中的疗效和特异性 IgG4 的增加似乎与 Dpg-Pol 过敏原提取物中主要过敏原的存在有关。